(Q33236634)

English

Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: an observational study

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

24 July 2017

Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: an observational study (English)

1 reference

Europe PubMed Central

24 July 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Robert M. Mader

object named as

Robert Mader

9

0 references

author name string

Rupert Bartsch

1

1 reference

Europe PubMed Central

24 July 2017

Catharina Wenzel

2

1 reference

Europe PubMed Central

24 July 2017

Dagmar Hussian

3

1 reference

Europe PubMed Central

24 July 2017

Ursula Pluschnig

4

1 reference

Europe PubMed Central

24 July 2017

Ursula Sevelda

5

1 reference

Europe PubMed Central

24 July 2017

Wolfgang Koestler

6

1 reference

Europe PubMed Central

24 July 2017

Gabriela Altorjai

7

1 reference

Europe PubMed Central

24 July 2017

Gottfried J Locker

8

1 reference

Europe PubMed Central

24 July 2017

Christoph C Zielinski

10

1 reference

Europe PubMed Central

24 July 2017

Guenther G Steger

11

1 reference

Europe PubMed Central

24 July 2017

language of work or name

0 references

publication date

15 March 2006

1 reference

Europe PubMed Central

24 July 2017

1 reference

Europe PubMed Central

24 July 2017

6

1 reference

Europe PubMed Central

24 July 2017

63

1 reference

Europe PubMed Central

24 July 2017

https://scigraph.springernature.com/pub.10.1186/1471-2407-6-63

0 references

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1431554

21 June 2018

Utilizing prognostic and predictive factors in breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1431554

21 June 2018

Targeting c-erbB2 and other receptors of the c-erbB family: rationale and clinical applications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1431554

21 June 2018

Reversing resistance to targeted therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1431554

21 June 2018

Rational surveillance programs for early stage breast cancer patients after primary treatment.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1431554

21 June 2018

Prognostic and predictive factors in early-stage breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1431554

21 June 2018

Molecular approach to breast cancer treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1431554

21 June 2018

Monoclonal antibodies, small molecules, and vaccines in the treatment of breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1431554

21 June 2018

Use of trastuzumab beyond disease progression: observations from a retrospective review of case histories

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1431554

21 June 2018

Trastuzumab-based combination therapy for breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1431554

21 June 2018

Combination of Trastuzumab and Vinorelbine in Metastatic Breast Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1431554

21 June 2018

Clinical Experience with Trastuzumab (Herceptin)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1431554

21 June 2018

Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the hellenic cooperative oncology group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1431554

21 June 2018

Trastuzumab-Based Combinations in Metastatic Breast Cancer: How to Make a Choice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1431554

21 June 2018

Trastuzumab/chemotherapy combinations in metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1431554

21 June 2018

Trials of new combinations of Herceptin in metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1431554

21 June 2018

New combinations with Herceptin in metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1431554

21 June 2018

Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: pivotal trial data

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1431554

21 June 2018

Health-related quality of life as a treatment endpoint in metastatic breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1431554

21 June 2018

A study of quality of life in cancer patients receiving palliative chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1431554

21 June 2018

Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-6-63

21 January 2018

Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2(+) metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-6-63

21 January 2018

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-6-63

21 January 2018

Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-6-63

21 January 2018

Mechanisms of resistance development against trastuzumab (Herceptin) in an in vivo breast cancer model.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1431554

31 October 2018

Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1431554

31 October 2018

Pharmacokinetics, Safety, and Efficacy of Trastuzumab Administered Every Three Weeks in Combination With Paclitaxel

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-6-63

21 January 2018

[The frequency of cancer in France in year 2000, and trends since 1950]

1 reference

https://pubmed.ncbi.nlm.nih.gov/16539726

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1471-2407-6-63

1 reference

Europe PubMed Central

24 July 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

24 July 2017

1 reference

Europe PubMed Central

24 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33236634&oldid=1561177840"